PharmacokineticsPADECMONCT06426836
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
A study testing Amoxicillin-clavulanate, Piperacillin-tazobactam and Meropenem in people with Pharmacokinetics and Amoxicillin-clavulanate, run by University Hospital, Ghent at 3 sites in Belgium.
Trial summary
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO). Read more about this study
- Who is it for?
- Ages Up to 15 years
- Conditions the study is for
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam
- What is being tested?
- Amoxicillin-clavulanate, Piperacillin-tazobactam and Meropenem
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 3 sitesBelgium
- Study dates
- 19 Aug 2016to 1 Jul 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 15 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- patients admitted to the pediatric intensive care unit or cardiac intensive care unit
- patient age : 1,8 kg-15 years
- patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
- intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
- extracorporeal membrane oxygenation circuit
Who cannot join
- no catheter in place for blood sampling
- absence of parental/patient consent
- known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium3 sites, 3 recruiting
- Recruiting
Queen Fabiola Children's University Hospital
Brussels, Brussels Capital, 1020
Biarent Dominique, dominique.biarent@huderf.be
Vens Daphne, daphnevania.vens@huderf.be
- Recruiting
University Hospital
Ghent, 9000
Pieter De Cock, pieter.decock@uzgent.be
- Recruiting
Universitair hospital
Leuven, 3000
Debaveye Yves, yves.debaveye@uzleuven.be
About this study
Official title: Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
Read the detailed description
The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.
- Conditions
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem, Cefazolin, Teicoplanin
- Being tested
- Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem, Cefazolin, Vancomycin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Amoxicillin-clavulanateOther
Also called Blood sampling
blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
Piperacillin-tazobactamOther
Also called Blood sampling
blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
MeropenemOther
Also called Blood sampling
blood sampling in patients receiving meropenem as part of routine clinical care.
CefazolinOther
Also called Blood sampling
blood sampling in patients receiving cefazolin as part of routine clinical care.
VancomycinOther
Also called Blood sampling
blood sampling in patients receiving vancomycin as part of routine clinical care.
TeicoplaninOther
Also called Blood sampling
blood sampling in patients receiving teicoplanin as part of routine clinical care.
CiprofloxacinOther
Also called Blood sampling
blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
AmikacinOther
Also called Blood sampling
blood sampling in patients receiving amikacin as part of routine clinical care.
| Study group | Role | What they receive |
|---|---|---|
| Amoxicillin-clavulanate | Other | Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling Receives: Other: Amoxicillin-clavulanate |
| Piperacillin-tazobactam | Other | Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling Receives: Other: Piperacillin-tazobactam |
| Meropenem | Other | Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling Receives: Other: Meropenem |
| Cefazolin | Other | Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling Receives: Other: Cefazolin |
| Vancomycin | Other | Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling Receives: Other: Vancomycin |
| Teicoplanin | Other | Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling Receives: Other: Teicoplanin |
| Ciprofloxacin | Other | Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling Receives: Other: Ciprofloxacin |
| Amikacin | Other | Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling Receives: Other: Amikacin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions
Measured: up to 1 month
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Measured: July 2026
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions
Measured: July 2026
Secondary outcomes (11)
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a percentage of time during which the unbound concentration remains above the Minimal Inhibitory Concentration (MIC) of the micro-organism of at least 50% and a maximum concentration of 10 x MIC
Measured: up to 1 month
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of ciprofloxacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 86
Measured: up to 1 month
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of vancomycin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 200 to 300
Measured: up to 1 month
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of teicoplanin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is an Area-under the concentration-Time Curve of 900
Measured: up to 1 month
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of amikacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a peak over Minimal Inhibitory Concentration Ratio of 8 to 10, trough concentration below 5 mg/L and Area under the Concentration Time Curve/MIC>399
Measured: up to 1 month
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in first dose conditions
Measured: up to 1 month
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions
Measured: up to 1 month
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions
Measured: up to 1 month
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions
Measured: up to 1 month
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions
Measured: up to 1 month
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions
Measured: up to 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2024
- Study start19 Aug 2016
- Primary completion1 Jul 2029 (estimated)
- Study completion1 Jul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PharmacokineticsStudies of the same condition, open and under way.
- More trials run by University Hospital, GhentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Ghent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Annick de Jaeger, MD, Principal investigator, University Hospital, Ghent
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06426836
- Sponsor's protocol ID
- BC-03512 (EC 2015/0529)
- Acronym
- PADECMO
- Status last verified
- Sep 2026
- First submitted
- 13 May 2022
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation
- ClinicalTrials.gov ID
- NCT06426836
- Acronym / sponsor ID
- PADECMO / BC-03512 (EC 2015/0529)
- Conditions
- Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem, Cefazolin, Teicoplanin
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- University Hospital, GhentUniversity, hospital or other
- Study start
- 19 Aug 2016 (actual)
- Primary completion
- 1 Jul 2029 (estimated)
- Study completion
- 1 Jul 2029 (estimated)
- First posted
- 23 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
Detailed description
The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Amoxicillin-clavulanate | Other | Other: Amoxicillin-clavulanatePatients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling |
| Piperacillin-tazobactam | Other | Other: Piperacillin-tazobactamPatients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling |
| Meropenem | Other | Other: MeropenemPatients receiving meropenem as part of routine clinical care. Study procedure: blood sampling |
| Cefazolin | Other | Other: CefazolinPatients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling |
| Vancomycin | Other | Other: VancomycinPatients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling |
| Teicoplanin | Other | Other: TeicoplaninPatients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling |
| Ciprofloxacin | Other | Other: CiprofloxacinPatients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling |
| Amikacin | Other | Other: AmikacinPatients receiving amikacin as part of routine clinical care. Study procedure: blood sampling |
Who may qualify
- Ages
- Up to 15 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- patients admitted to the pediatric intensive care unit or cardiac intensive care unit
- patient age : 1,8 kg-15 years
- patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
- intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
- extracorporeal membrane oxygenation circuit
Key exclusion criteria (3 listed)
- no catheter in place for blood sampling
- absence of parental/patient consent
- known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Amoxicillin-clavulanateAlso: Blood samplingblood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care | Other | Amoxicillin-clavulanate |
| Piperacillin-tazobactamAlso: Blood samplingblood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care. | Other | Piperacillin-tazobactam |
| MeropenemAlso: Blood samplingblood sampling in patients receiving meropenem as part of routine clinical care. | Other | Meropenem |
| CefazolinAlso: Blood samplingblood sampling in patients receiving cefazolin as part of routine clinical care. | Other | Cefazolin |
| VancomycinAlso: Blood samplingblood sampling in patients receiving vancomycin as part of routine clinical care. | Other | Vancomycin |
| TeicoplaninAlso: Blood samplingblood sampling in patients receiving teicoplanin as part of routine clinical care. | Other | Teicoplanin |
| CiprofloxacinAlso: Blood samplingblood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care. | Other | Ciprofloxacin |
| AmikacinAlso: Blood samplingblood sampling in patients receiving amikacin as part of routine clinical care. | Other | Amikacin |
Primary outcome
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Time frame: up to 1 month
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Time frame: up to 1 month
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Time frame: up to 1 month
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Time frame: up to 1 month
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
Time frame: up to 1 month
% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Time frame: up to 1 month
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Time frame: up to 1 month
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Time frame: up to 1 month
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Time frame: July 2026
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Time frame: July 2026
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions
11 secondary outcomes
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
Time frame: up to 1 month
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
Time frame: up to 1 month
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
Time frame: up to 1 month
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
Time frame: up to 1 month
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
Time frame: up to 1 month
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
Time frame: up to 1 month
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Time frame: up to 1 month
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Time frame: up to 1 month
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Time frame: up to 1 month
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Time frame: up to 1 month
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Time frame: up to 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Pharmacokinetics
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingPhase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Annick de Jaeger, MD principal investigator
University Hospital, Ghent
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Amoxicillin-clavulanate, Piperacillin-tazobactam and Meropenem in people with Pharmacokinetics and Amoxicillin-clavulanate, run by University Hospital, Ghent at 3 sites in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pieter De Cock, PharmD (+32 9 332 29 69, pieter.decock@uzgent.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism (time frame: up to 1 month). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.